Pre-clinical and clinical data suggest that the development of a safe and effective A?-immunotherapy for AD requires anti- A? antibodies, while avoiding proinflammatory adjuvants and autoreactive T cells which are believed to be responsible for the adverse events (meningoenchephalitis) that occurred in response to the AN1792 clinical trial in AD patients. Our prototype Peptide epitope Vaccine (PepVac) and DNA epitope Vaccine (DepVac) were designed with three copies of the self-B cell epitope of A?, A?1-11, in tandem with a promiscuous foreign T cell epitope, PADRE, linked to the powerful anti-inflammatory molecular adjuvant, macrophage derived chemokine (CCL22). Our tripartite DepVac approach induced robust anti-A? antibody titers in transgenic mouse models of AD. Unfortunately, the AN1792 clinical trial also suffered from a low number of responders and generally low titers in those that did respond to the AN1792 vaccine. Thus future clinical trials need to address the prevalence of immunosenescence in the elderly to insure both the safety and the success of the vaccine. In order to overcome serious concerns regarding the limited ability of the elderly to mount an effective immune response to active immunization, we propose to take advantage of pre-existing memory CD4+T helper (Th) cells that were generated in response to conventional public health vaccination programs and/or infections with various pathogens. Thus in our new approach we have engineered modified PepVac and DepVac that contain Multiple Th epitopes that are expected to activate memory Th cells, which will then provide Th stimulation of B cells expressing Ig receptors for the A?1-11, B cell epitope. These third generation vaccine candidates have been designated MPepVac and MDepVac to indicate the use Multiple Th epitopes. Thus, the goals of this renewal proposal are: 1) to demonstrate the feasibility of pre-existing memory CD4+Th cells in aged animal models to induce a rapid and robust anti- A? antibody response;2) to examine the safety and efficacy of MDepVac and/or MPepVac in Tg2576 mice and rabbits, which represent an excellent larger animal model compared to rodent to show feasibility to scale up DNA immunization;3) to compare intramuscular versus intradermal DNA immunization using electroporation system that is currently being used in human clinical trials for other vaccine applications. Ultimately we believe that the further refinement our AD DNA- and protein-based epitope vaccine candidates will facilitate translation to human clinical trials in either very early AD, or preferably to preclinical stage individuals identified by validated AD biomarkers.
Alzheimer's Disease is the major cause of dementia in the US and characterized by progressive cognitive decline that impacts memory, language, judgment, orientation to time and place, etc. Pathologically there is an increase in the presence in amyloid plaques, neurofibrillary tangles, dystrophic neurites and a general loss of neurons. In current project we propose to generate safe and effective epitope vaccine that may prevent/reduce development of Alzheimer's disease pathology in pre-symptomatic people diagnosed with early-stage AD.
|Davtyan, Hayk; Zagorski, Karen; Petrushina, Irina et al. (2017) MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. Neurobiol Aging 59:156-170|
|Petrushina, Irina; Davtyan, Hayk; Hovakimyan, Armine et al. (2017) Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of ?-Amyloid in an Animal Model of Alzheimer's Disease. Mol Ther 25:153-164|
|Agadjanyan, Michael G; Zagorski, Karen; Petrushina, Irina et al. (2017) Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. Mol Neurodegener 12:33|
|Davtyan, Hayk; Chen, Wesley W; Zagorski, Karen et al. (2017) MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine 35:2015-2024|
|Davtyan, Hayk; Zagorski, Karen; Rajapaksha, Harinda et al. (2016) Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A? pathological molecules. Sci Rep 6:28912|
|Agadjanyan, Michael G; Petrovsky, Nikolai; Ghochikyan, Anahit (2015) A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement 11:1246-59|
|Ghochikyan, Anahit; Petrushina, Irina; Davtyan, Hayk et al. (2014) Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human ?-synuclein: feasibility study. Neurosci Lett 560:86-91|
|Davtyan, Hayk; Ghochikyan, Anahit; Petrushina, Irina et al. (2014) The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. Alzheimers Dement 10:271-83|
|Evans, Claire F; Davtyan, Hayk; Petrushina, Irina et al. (2014) Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques. Alzheimers Dement 10:284-95|
|Davtyan, Hayk; Ghochikyan, Anahit; Hovakimyan, Armine et al. (2014) A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-?-amyloid antibody responses in mice with pre-existing virus specific memory. J Neuroimmunol 277:77-84|
Showing the most recent 10 out of 52 publications